Multiple myeloma
Top Cited Papers
Open Access
- 15 March 2008
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 111 (6), 2962-2972
- https://doi.org/10.1182/blood-2007-10-078022
Abstract
Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present aKeywords
This publication has 106 references indexed in Scilit:
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969